Page last updated: 2024-10-24

death effector domain binding

Definition

Target type: molecularfunction

Binding to a DED domain (death effector domain) of a protein, a homotypic protein interaction module composed of a bundle of six alpha-helices that is related in structure to the death domain (DD). [GOC:ecd, InterPro:IPR001875]

Death effector domain (DED) binding is a crucial molecular interaction that plays a pivotal role in the regulation of apoptosis, a programmed cell death process essential for maintaining cellular homeostasis. DEDs are conserved protein-protein interaction domains found in a variety of proteins involved in apoptosis signaling pathways. These domains facilitate the assembly of protein complexes, which in turn orchestrate the execution of the apoptotic program. DED-containing proteins can interact with each other through their DEDs, forming homo- or hetero-dimers or even larger oligomers. This interaction is highly specific, ensuring that the correct proteins assemble into functional complexes. The formation of these complexes triggers a cascade of events, culminating in the activation of caspases, a family of cysteine proteases that execute the apoptotic program by cleaving specific cellular substrates. DED-mediated interactions are critical for the proper activation and regulation of caspases, ensuring that apoptosis is initiated only when necessary and proceeds in a controlled manner. Moreover, DED binding contributes to the precise localization of apoptotic signaling components within cells, enabling efficient and targeted execution of the apoptotic program. This intricate interplay of DED-mediated interactions underlines the critical role of DED binding in orchestrating the complex and tightly regulated process of apoptosis.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Caspase-10A caspase-10 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q92851]Homo sapiens (human)
Caspase-8A caspase-8 that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)

Compounds (16)

CompoundDefinitionClassesRoles
3,3',4,5'-tetrahydroxystilbenestilbenoid
isoquinoline-1,3,4-trioneisoquinoline-1,3,4-trione: structure in first source
n-methylisatinN-methylisatin: structure given in first source
2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid: structure given in first source
stictic acidstictic acid: antioxidant from lichen, Usnea articulata; structure in first sourcearomatic ether
pralnacasanpralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source
1,3(2h,4h)-isoquinolinedione1,3(2H,4H)-isoquinolinedione: structure in first source
acetyl-aspartyl-glutamyl-valyl-aspartalAc-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.

acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor
tetrapeptideprotease inhibitor
1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dionepyrimidotriazine
1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dionepyrimidotriazine
5-Nitroisatinindolesanticoronaviral agent
n-acetyltyrosyl-valyl-alanyl-aspartyl aldehyde
benzyloxycarbonyl-phe-ala-fluormethylketonecathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
grassystatin agrassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source
MK-8353MK-8353 : A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors.

MK-8353: ERK inhibitor used in oncology
aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor